NeuroSense (NASDAQ: NRSN) files Form 6-K with AGM notice and proxy materials

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. furnished a Form 6-K to provide materials for its upcoming Annual General Meeting of Shareholders scheduled for September 25, 2025. The filing attaches and incorporates a Notice and Proxy Statement for the meeting, along with a proxy card that shareholders can use to vote on the matters presented.

The company also states that this Form 6-K is incorporated by reference into several of its existing registration statements on Form S-8 and Form F-3, meaning the information in this report is now formally part of those securities offering documents.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_________________

FORM 6-K

_________________

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of August 2025

Commission File Number: 001-41084

_________________

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

_________________

NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

_________________

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Attached hereto and incorporated herein by reference are the following exhibits:

Exhibit 99.1		Notice and Proxy Statement for the Annual General Meeting of Shareholders of the registrant scheduled for September 25, 2025
Exhibit 99.2		Proxy Card

This Report on Form 6-K is hereby incorporated by reference into registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		NeuroSense Therapeutics Ltd.
Date: August 21, 2025		By:		/s/ Alon Ben-Noon
				Alon Ben-Noon
				Chief Executive Officer

2

FAQ

What does NeuroSense Therapeutics (NRSN) report in this Form 6-K?

NeuroSense Therapeutics Ltd. furnishes a Form 6-K that provides the Notice and Proxy Statement for its Annual General Meeting of Shareholders and a related proxy card.

When is the NeuroSense Therapeutics (NRSN) Annual General Meeting scheduled?

The Annual General Meeting of Shareholders of NeuroSense Therapeutics Ltd. is scheduled for September 25, 2025, according to the attached notice and proxy statement.

Which documents are attached to this NeuroSense Therapeutics (NRSN) Form 6-K?

The Form 6-K includes as exhibits a Notice and Proxy Statement for the Annual General Meeting of Shareholders and a Proxy Card.

How is this Form 6-K used in NeuroSense Therapeutics (NRSN) registration statements?

The company states that this Form 6-K is incorporated by reference into its Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File Nos. 333-269306, 333-260338, 333-283656 and 333-284051).

Does this NeuroSense Therapeutics (NRSN) Form 6-K include financial results?

No, this Form 6-K focuses on the Annual General Meeting materials and the incorporation of the report into existing registration statements, not on financial results.

Who signed the NeuroSense Therapeutics (NRSN) Form 6-K?

The Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon, Chief Executive Officer.